Drug Trial Radar · NCT06669975
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Dec 1, 2026
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- AP Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
AP402 (Part 1 Dose esclation)Drug
Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
AP402 (Part 2 Dose Expansion)Drug
After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate of Maximum tolerated dose (MTD)Time frame: Baseline to 90 days after the last dose
- Number of participants with Adverse events (AEs) and Serious Adverse events (SAE) as assessed by CTCAE V5Time frame: Baseline to 90 days after the last dose
- To evaluate R2PD based on PK parameters- Cmax (Maximum plasma concentration)Time frame: Baseline to 90 days after the last dose
- To evaluate R2PD based on PK parameters- Tmax (time for maximum concentration)Time frame: Baseline to 90 days after the last dose
- To evaluate R2PD based on PK parameters- AUC (Area under curve)Time frame: Baseline to 90 days after the last dose
- To evaluate R2PD based on PK parameters- T1/2 (terminal half-life)Time frame: Baseline to 90 days after the last dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Macquarie University Clinical Trials Unit
Macquarie, New South Wales, Australia · Not yet recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Not yet recruiting
Linear Clinical Research
Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.